Advertisement
LGND vs PHAR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LGND is a Buy and PHAR is a Buy.
LGND in upward trend: 10-day moving average crossed above 50-day moving average on September 28, 2026
The 10-day moving average for LGND crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LGND as a result. In 69 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for LGND just turned positive on October 21, 2026. Looking at past instances where LGND's MACD turned positive, the stock continued to rise in 32 of 49 cases over the following month. The odds of a continued upward trend are 65%.
LGND moved above its 50-day moving average on September 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in 258 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for LGND moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 26 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
LGND broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LGND entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.486) is normal, around the industry mean (2.988). P/E Ratio (31.013) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (1.267) is also within normal values, averaging (9.059). Dividend Yield (0.006) settles around the average of (123.903) among similar stocks. P/S Ratio (20.325) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
PHAR's RSI Indicator ascends from oversold territory
The RSI Oscillator for PHAR moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 13 similar instances when the indicator left oversold territory. In 12 of the 13 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where PHAR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for PHAR just turned positive on October 20, 2026. Looking at past instances where PHAR's MACD turned positive, the stock continued to rise in 46 of 61 cases over the following month. The odds of a continued upward trend are 75%.
Following a +0.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAR advanced for three days, in 169 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
PHAR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for PHAR entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. PHAR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.481) is normal, around the industry mean (2.988). PHAR has a moderately high P/E Ratio (67.962) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.080) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (2.168) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LGND | PHAR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 38 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | 100 | |
SMR RATING 1..100 | 44 | 86 | |
PRICE GROWTH RATING 1..100 | 38 | 79 | |
P/E GROWTH RATING 1..100 | 94 | 96 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LGND's Valuation (91) in the Biotechnology industry is in the same range as PHAR (93) in the null industry. This means that LGND’s stock grew similarly to PHAR’s over the last 12 months.
LGND's Profit vs Risk Rating (4) in the Biotechnology industry is significantly better than the same rating for PHAR (100) in the null industry. This means that LGND’s stock grew significantly faster than PHAR’s over the last 12 months.
LGND's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for PHAR (86) in the null industry. This means that LGND’s stock grew somewhat faster than PHAR’s over the last 12 months.
LGND's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for PHAR (79) in the null industry. This means that LGND’s stock grew somewhat faster than PHAR’s over the last 12 months.
LGND's P/E Growth Rating (94) in the Biotechnology industry is in the same range as PHAR (96) in the null industry. This means that LGND’s stock grew similarly to PHAR’s over the last 12 months.
| LGND | PHAR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 62% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 79% | N/A |
| MACD ODDS (%) | 2 days ago 65% | 2 days ago 75% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 76% |
| Advances ODDS (%) | 2 days ago 76% | 25 days ago 72% |
| Declines ODDS (%) | 9 days ago 68% | 4 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LGND’s FA Score shows that 1 FA rating(s) are green while PHAR’s FA Score has 0 green FA rating(s).
- LGND’s FA Score: 1 green, 4 red.
- PHAR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LGND’s TA Score shows that 5 TA indicator(s) are bullish while PHAR’s TA Score has 5 bullish TA indicator(s).
- LGND’s TA Score: 5 bullish, 5 bearish.
- PHAR’s TA Score: 5 bullish, 2 bearish.
Price Growth
LGND (@Biotechnology) experienced а +6.71% price change this week, while PHAR (@Biotechnology) price change was -1.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
LGND is expected to report earnings on Oct 29, 2026.
PHAR is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LGND and
Correlation & Price change
A.I.dvisor indicates that over the last year, LGND has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To LGND | 1D Price Change % | ||
|---|---|---|---|---|
| LGND | 100% | +2.73% | ||
| AXON - LGND | 49% Loosely correlated | +2.54% | ||
| VCYT - LGND | 41% Loosely correlated | +3.19% | ||
| TVTX - LGND | 41% Loosely correlated | +0.54% | ||
| ABCL - LGND | 37% Loosely correlated | +4.53% | ||
| TRDA - LGND | 36% Loosely correlated | -6.81% | ||
More | ||||
PHAR and
Correlation & Price change
A.I.dvisor indicates that over the last year, PHAR has been loosely correlated with ENGN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAR jumps, then ENGN could also see price increases.
| Ticker / NAME | Correlation To PHAR | 1D Price Change % | ||
|---|---|---|---|---|
| PHAR | 100% | -1.86% | ||
| ENGN - PHAR | 43% Loosely correlated | -2.40% | ||
| TRDA - PHAR | 42% Loosely correlated | -6.81% | ||
| LKFT - PHAR | 35% Loosely correlated | -0.55% | ||
| LGND - PHAR | 34% Loosely correlated | +2.73% | ||
| INSM - PHAR | 34% Loosely correlated | -1.70% | ||
More | ||||